Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

• Main Authors: Glen J. Weiss (Author), Raoul Tibes (Author), Lisa Blaydorn (Author), Gayle Jameson (Author), Molly Downhour (Author), Erica White (Author), Ivor Caro (Author), Daniel D. Von Hoff (Author)
• Format: Book
• Published: PAGEPress Publications, 2011-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...